DDMAC scolds Allergan, Pfizer on promos; Roche's Ian Clark exits Dendreon board;

 @FiercePharma: Sanofi to shutter PA R&D site, cut 400 jobs. Article | Follow @FiercePharma

> The FDA's marketing arm cited Wyeth (now Pfizer) for exaggerating the effectiveness of Premarin in a patient-testimonial video and scolded Allergan for overstating efficacy and minimizing risks of its eye drug Acuvail in a journal ad. Story

> Even as it moves to shed 1,000 jobs by the end of next year, Genzyme is accelerating the hiring of manufacturing and quality control workers in Massachusetts, where it recently built a plant in Framingham and expanded its Allston Landing site. News

> Seattle-based Dendreon (NASDAQ: DNDN) said that Ian Clark, CEO of Roche's U.S.-based Genentech unit, is resigning from the Dendreon board. Dendreon release | Story

> U.S. regulators postponed a key decision on AstraZeneca's experimental blood thinner Brilinta by three months, but the drugmaker remains confident about the product's application for market approval. News | Report

> Sun Pharma made a fresh offer to shareholders of Israel's Taro Pharma to buy remaining shares that were not tendered by its shareholders during the latest offer, which expired Wednesday. Sun release | Article

> K-V Pharmaceutical has reached a $20 million loan agreement in the wake of a recent FDA approval as the struggling specialty-drug company seeks to recover from regulatory and compliance issues. Article

> Savient Pharmaceuticals, an unprofitable biotechnology company that is seeking buyers, won U.S. approval for a gout drug that analysts estimate may generate almost $1 billion a year. Report | Story

> GlaxoSmithKline has won a $21.3 million contract to provide medical supplies to the U.S. Army, Navy and Air Force, the Defense Department says. Item

> Aspen Pharmacare, Africa's biggest generic drug maker, reported a 24 percent rise in full-year profit, boosted by its South African unit and says it expects strong demand in the coming year. News

Biotech News

@FierceBiotech: Do rich markets lure biotechs away from low-cost remedies? Article | Follow @FierceBiotech

@JohnCFierce: ARNA shares down about 40 percent. This is one tough development field. | Follow @JohnCFierce

> Neurocrine depression drug disappointing in Ph2. Article

> CTI will appeal FDA pixantrone ruling. Item

> CEO: Roche, Genentech R&D won't merge. Report

> Beer becomes Aegerion CEO. Story

> Ramius raises offer for Cypress. News

Drug Discovery News

> Non-animal gelatin a sweet treat for drug release. Report

> 'Superbowl' drug delivery controls free radicals. Story

> FDA warns e-cigarette makers to follow the law. Article

> OctoPlus snares a 'top 5' pharma firm for PolyActive tech. News

> Biodegradable and programmable, organic thin films show promise. Article

> TransPharma has successful diabetes trial. Item

Medical Device News

@FierceMedDev: TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech. News | Follow @FierceMedDev

> Medtronic scores win in SSI case. News

> Tryton raises $20M for stent system development. Report

> Fat freezing system OKed by FDA. Story

> Toomey targets device tax in Senate bid. Article

> Response Biomedical to cut 25 percent of workforce. News

> SMU, DOD look to help amputees. Story

> PediaWorks, Medikit form JV to develop pediatric devices. Item

And Finally... After decades of debate, the FDA appears poised to issue its strongest guidelines on animal antibiotics yet, intended to reduce what it calls a clear risk to human health. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.